Benzinga | Mar 26, 2021 08:33AM EDT

Citigroup Initiates Coverage On Forte Biosciences with Buy Rating, Announces Price Target of $75

Citigroup analyst Mohit Bansal initiates coverage on Forte Biosciences (NASDAQ:FBRX) with a Buy rating and announces Price Target of $75.